Polynovo (PNV.AX) Stock Price
Polynovo Price
Revenue has compounded at 72.9% per year over the past 19 years to 143.71 M AUD. Earnings per share have grown at 18.3% per year over the last 2 years. Polynovo's net margin stands at 5.1%, up from -2.9% several years earlier. Analysts set a median price target of 2.04 AUD, implying 118.2% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
Polynovo stock price
Polynovo business model & stock analysis
Frequently asked questions about Polynovo
The business model of Polynovo Ltd, an Australian medical device company, is centered around the development, manufacturing, and commercialization of its innovative biodegradable polymer technologies for the medical industry. Polynovo's core product is NovoSorb, a revolutionary biomaterial that can be used in various medical applications, such as wound management, surgical procedures, and tissue regeneration. By harnessing the benefits of NovoSorb, Polynovo aims to provide healthcare professionals with advanced solutions that improve patient outcomes and reduce healthcare costs. With its focus on research, technology, and collaboration, Polynovo Ltd strives to establish itself as a leading player in the global medical device market.
Polynovo Ltd is primarily active in the medical industry, specifically specializing in the development, manufacturing, and commercialization of medical devices. The company's innovative technologies focus on the treatment of acute and chronic wounds, including burns, surgical wounds, and skin defects. Polynovo's products, such as its leading NovoSorb BTM technology, offer surgeons and patients advanced wound healing solutions. With a strong commitment to research and development, Polynovo aims to cater to the growing global demand for effective wound care and tissue regeneration products.
The main competitors of Polynovo Ltd in the market include larger medical device companies such as Johnson & Johnson, Medtronic, and Zimmer Biomet. These companies also offer innovative and competitive products in the field of medical device manufacturing. However, Polynovo Ltd distinguishes itself with its unique patented NovoSorb platform, which is highly regarded for its biocompatible and bioresorbable capabilities. Polynovo Ltd aims to revolutionize the market with its innovative medical solutions, providing patients with advanced options for wound care and tissue repair.
Polynovo Ltd is an Australian medical device company specializing in the design, development, and manufacturing of dermal regeneration solutions. Established in 1998, Polynovo has become a global leader in its field, with its flagship product NovoSorb® BTM gaining significant recognition. This innovative biodegradable scaffold facilitates the regeneration of full-thickness skin and helps treat various wounds, burns, and surgical incisions. Polynovo's commitment to advanced technology, research, and development has enabled them to establish a strong presence in international markets, providing medical professionals and patients with effective and lasting solutions for improved healing outcomes.
Polynovo Ltd has achieved several significant milestones in recent years. First and foremost, the company successfully developed and commercialized its innovative NovoSorb BTM technology. This breakthrough technology has revolutionized the treatment of complex wounds, allowing for faster and more effective healing. Another notable milestone for Polynovo Ltd was its expansion into international markets, securing regulatory approvals in Europe, the United States, and other key regions. Additionally, the company has formed strategic partnerships with global healthcare companies, further strengthening its position in the market. These achievements demonstrate Polynovo Ltd's commitment to providing cutting-edge solutions for wound care management and its continuous growth in the industry.
Polynovo Ltd is primarily present in Australia and the United States.
Polynovo Ltd represents a strong set of values and an innovative corporate philosophy. The company is committed to delivering advanced medical solutions using their unique NovoSorb® technology platform. Polynovo focuses on improving patient outcomes by providing safe and effective products for the healthcare industry. Their dedication to research and development allows them to create cutting-edge solutions that address critical needs in wound healing and soft tissue repair. With a customer-centric approach, Polynovo strives to make a positive impact on healthcare by offering innovative products and maintaining high standards of quality, safety, and ethics.
Analysts currently set an average price target of 1.97 AUD for the Polynovo stock (median: 2.04 AUD), implying +111.2 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Polynovo stock: 9 recommend buying, 2 holding and 0 selling.
Converted at the current exchange rate, the Polynovo share trades at 0.58 EUR (0.94 AUD).
The Polynovo share (PNV.AX) is listed on 5 stock exchanges, including: SIX (Zürich) (MFJ.SW), ASX (PNV.AX), Frankfurt (MFJ.F), München (MFJ.MU).
Polynovo Ltd is an Australian company specializing in the manufacture of medical products. The company's business model is based on offering various products divided into three main areas: wound care, surgery, and traumatology. Polynovo develops innovative and advanced medical products for wound healing, surgery, and traumatology. The company uses bioresorbable materials to accelerate the healing process and reduce the risk of infections. Polynovo invests significant resources in research and development to maintain technological leadership in this field. The company sells its products directly to hospitals, healthcare providers, wound healing and surgery professionals. Polynovo aims to expand its reach and enter new markets to promote business growth. The company's business model is focused on solving people's health issues and enabling a better life.
The revenue of Polynovo is 143.71 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Polynovo is 7.34 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Polynovo is currently 88.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Polynovo stock.
The price-to-sales ratio (P/S) of Polynovo is currently 4.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Polynovo stock.
The Eulerpool Quality Score for Polynovo is 7/10.
The ISIN of Polynovo is AU000000PNV0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Polynovo is A12F4T. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Polynovo is PNV.AX. The ticker symbol is used to trade Polynovo shares on the stock exchange.
Polynovo stock
Polynovo Peer Group
Polynovo Ticker
Polynovo FIGI
All fundamentals and in-depth analysis of Polynovo
Our stock analysis for Polynovo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Polynovo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.